Collins Helen Louise bought ELVN
March 25, 2026 · Form 4 insider transaction
Collins Helen Louise bought 40,000 shares of Enliven Therapeutics, Inc. at $2.48 per share, a transaction worth $99.2K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
40,000
Price
$2.48
Total value
$99.2K
InsiderCollins Helen Louise
RoleOfficer, Director
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateMarch 25, 2026
Filing dateMarch 27, 2026
Shares owned after65,000
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.; Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.